secwatch.observer — SEC 8-K summary
======================================

Issuer:     Maze Therapeutics, Inc. (MAZE)
CIK:        0001842295
Form:       8-K
Filed at:   2026-08-17T20:16:30+00:00
Accession:  0001193125-26-354092
Event type: leadership
Sentiment:  neutral
Materiality: 0.40
Item codes: 5.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Maze Therapeutics appoints Paula Johnson and Sophie Kornowski to board; pipeline milestones ahead
--------------------------------------------------------------------------------

- Paula Johnson, M.D., M.P.H., and Sophie Kornowski, Pharm.D., M.B.A., appointed to Maze's board effective Aug 13, 2026.
- Johnson is President of Wellesley College and J&J board member; Kornowski ex-CEO of Boston Pharmaceuticals, led GSK acquisition.
- Board class changes: Nancy Andrews moved to Class II, Hervé Hoppenot to Class III to balance classes.
- CEO Jason Coloma cites upcoming data: MZE829 in AMKD late 2026/early 2027, MZE782 initial data in 2027.
- Each new director receives pro-rata $40k cash retainer and option for 36,000 shares vesting monthly over 3 years.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1842295/000119312526354092/0001193125-26-354092-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1842295/000119312526354092/d135740d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-354092

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer